Literature DB >> 27644564

The effect of acotiamide on epigastric pain syndrome and postprandial distress syndrome in patients with functional dyspepsia.

Satoshi Shinozaki1, Hiroyuki Osawa, Hirotsugu Sakamoto, Yoshikazu Hayashi, Alan Kawarai Lefor, Hironori Yamamoto.   

Abstract

The effect of acotiamide on gastrointestinal symptoms is undefined. The aim of this study is to evaluate the effect of acotiamide on abdominal symptoms in patients with functional dyspepsia. We retrospectively reviewed 51 patients treated with acotiamide. We evaluated patient quality of life using the Izumo scale that detects changes in quality of life caused by abdominal symptoms. Acotiamide ameliorated the symptoms of functional dyspepsia at one and three months (improved: 61% vs 80%, p=0.029 and resolved: 17% vs 33%, p=0.069). We then evaluated the effect of acotiamide on epigastric pain syndrome (EPS) (n=33) and postprandial distress syndrome (PDS) (n=41). Acotiamide treatment showed an early effect on rates of improvement (63%) and resolution (42%) of EPS symptoms at one month, maintained up to three months (69% and 39%, respectively). Both rates of improvement and resolution of PDS symptoms showed a significant increase from one month to three months (56% vs 78%, p=0.021 and 17% vs 46%, p=0.004, respectively). The severity of functional dyspepsia symptoms before treatment was significantly associated with failed resolution of functional dyspepsia symptoms (p=0.013). Acotiamide improves and resolves EPS symptoms as well as PDS symptoms. PDS symptoms take longer to resolve than EPS symptoms. J. Med. Invest. 63: 230-235, August, 2016.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27644564     DOI: 10.2152/jmi.63.230

Source DB:  PubMed          Journal:  J Med Invest        ISSN: 1343-1420


  5 in total

1.  Long-term vonoprazan therapy is effective for controlling symptomatic proton pump inhibitor-resistant gastroesophageal reflux disease.

Authors:  Satoshi Shinozaki; Hiroyuki Osawa; Yoshikazu Hayashi; Yoshimasa Miura; Alan Kawarai Lefor; Hironori Yamamoto
Journal:  Biomed Rep       Date:  2021-02-01

2.  Vonoprazan 10 mg daily is effective for the treatment of patients with proton pump inhibitor-resistant gastroesophageal reflux disease.

Authors:  Satoshi Shinozaki; Hiroyuki Osawa; Yoshikazu Hayashi; Hirotsugu Sakamoto; Yasutoshi Kobayashi; Alan Kawarai Lefor; Hironori Yamamoto
Journal:  Biomed Rep       Date:  2017-07-20

Review 3.  Prokinetics in the Management of Functional Gastrointestinal Disorders.

Authors:  Eamonn M M Quigley
Journal:  Curr Gastroenterol Rep       Date:  2017-09-08

Review 4.  Management of functional dyspepsia: state of the art and emerging therapies.

Authors:  Hiroshi Yamawaki; Seiji Futagami; Mako Wakabayashi; Noriko Sakasegawa; Shuhei Agawa; Kazutoshi Higuchi; Yasuhiro Kodaka; Katsuhiko Iwakiri
Journal:  Ther Adv Chronic Dis       Date:  2017-08-27       Impact factor: 5.091

5.  Efficacy of acotiamide on postprandial distress syndrome and epigastric pain syndrome depending on the estimated gastric acid secretion level.

Authors:  Toshiaki Suzuki; Reina Ohba; Ei Kataoka; Yui Kudo; Akira Zeniya; Daisuke Segawa; Keisuke Oikawa; Masaru Odashima; Taiji Saga; Tomoyuki Kuramitsu; Hideaki Sasahara; Kazuo Yoneyama; Takashi Tomita; Yosuke Shimodaira; Katsunori Iijima
Journal:  J Neurogastroenterol Motil       Date:  2022-01-30       Impact factor: 4.924

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.